1. Therapeutic applications of the selective high affinity ligand drug SH7139 extend beyond non-Hodgkin’s lymphoma to many other types of solid cancers
   Rod Balhorn et al, 2020, Oncotarget CrossRef
2. Evaluation of the UK Myeloma Research Alliance Risk Profile in Chinese Patients with Newly Diagnosed Multiple Myeloma without Autologous Stem Cell Transplantation
   Kewa Ma et al, 2021, OncoTargets and Therapy CrossRef
3. The Prognostic Value of Immunophenotypic Characteristics of Plasma Cells in Newly Diagnosed Multiple Myeloma Patients Treated with First-Generation Proteasome Inhibitor Bortezomib
   Galina Nikolaevna Salogub et al, 2022, Clinical oncohematology CrossRef